Insuffisance rénale chronique et maladie cardiovasculaire

Renal insufficiency is frequently seen in patients with cardiovascular disease. In contrast, coronary artery disease is the leading cause of death in patients with renal impairment. The recognition of renal insufficiency is essential in these patients and preventive measures must be put in place to prevent the progression or onset of cardiovascular disease. In this article, we explain the methods to assess kidney function, the epidemiology of coronary heart disease in patients with renal impairment, risk factors conventional and non-conventional found in these patients and the main recommendations for their therapeutic care.     

Voie radiale et insuffisance rénale

Patients with chronic kidney disease have a high cardiovascular risk and mortality. This problem is growing because of the aging of the population and prevalence of diabetes. Transradial approach is traditionally prohibited due to the injury that catheterization induces on this artery that could possibly influence its suitability as an arteriovenous fistula. Paradoxically, the increased risk of major vascular complications with femoral access leads to transgress this rule. Indeed, transradial approach by reducing dramatically the rate of vascular bleeding complications leads to a significant reduction of adverse events and mortality, especially in the high cardiovascular risk sub-group. In patients with chronic kidney disease, choice of vascular access site should compare the potentially fatal risk of vascular complications with the one of traumatizing the artery needed to create a distal hemodialysis access site. Thus, chronic renal insufficiency even on hemodialysis should not be an absolute contraindication to radial approach, which could be used individually by a skilled team and in a mini-invasive spirit. A large randomised study comparing radial and femoral access in this population is needed.     

Hypertension artérielle,atteinte rénale et génétique chez le sujet noir : mise au point

The incidence and prevalence of hypertension is markedly elevated in Afro-American populations vs Caucasians. The development of end-stage renal disease is also more frequent in Afro-American subjects, independently of blood pressure control. As compared to Caucasians, Afro-American subjects have a higher risk of end-stage renal disease when they are infected with HIV or have lupus. For decades, these data remained mysterious. Within the last 3 years, results from studies in the field of genetics and infectious diseases have transformed our view on this problem. The aim of this paper is to explain how these results have changed our understanding of hypertension and its consequences in Afro-American subjects.     

Contrôle de la pression artérielle chez le patient en insuffisance rénale chronique avancée : quelles données,quelles recommandations ?

Several epidemiological studies have indicated that high blood pressure is associated with deterioration of renal function in patients with renal disease. Target blood pressures in patients with renal diseases have been defined and proposed to the community in several national and international guidelines. However, some of these targets have been recently changed to take into account results of studies, including randomized clinical trials. The aim of this paper is to put into perspective the history of ideas regarding adequate blood pressure control in patients with renal disease in the light of these results, and explain how these trials have changed our perception, practice and guidelines.     

Influence de la fonction rénale sur la pertinence diagnostique du BNP chez l’insuffisant cardiaque âgé

Aim of the study

BNP levels are accurate in the diagnosis of heart failure and useful in clinical practice. Relationship between BNP, heart failure (HF) and renal function are little known in the elderly. Renal function influence the optimal cut point of BNP in patients with a Glomerular Filtration Rate (eGFR) lesser than 60 ml/min/1.73 m².

Methodology

A total of 71 patients (mean age = 85 years) were admitted in a Cardiogeriatric Unit. We noted several parameters, age, gender, the presence or the absence of Systolic Heart Failure (clinical history and physical examination), the echographic measure of the left ventricular ejection fraction, the eGFR value calculated by simplified MDRD formula and the BNP value. We divided these patients into six groups according the presence of HF and eGFR value higher than 60ml/min/1.73m²,or between 30 and 60 or between 15 and 30.

Results

Our results show that the BNP value is higher in all the three groups of patients with Heart Failure with or without diminution of the eGFR: for example, 1220 pg/ml in the presence of HF versus 788 pg/ml in the absence of HF in the two groups with the eGFR is calculated between 15 and 30 ml/min/1.73m².

Conclusion

BNP is a helpful tool in clinical practice for the diagnosis of Systolic Heart Failure in the presence of renal impairment in the elderly with a higher biomarker cut point.     

Théorie hormonale de l’insuffisance cardiaque à fonction systolique altérée

Heart failure (HF) is a major cause of morbidity and mortality in the developed countries. Hospital discharges and deaths from HF are regularly increasing. Therapies initially aimed at reversing hemodynamic abnormalities in HF, increasing cardiac output, decreasing intracardiac pressures, and blocking vasoconstriction. However, none of these therapies improved survival and some actually increased mortality. Now therapies for HF related to left ventricular systolic dysfunction have focused on counteracting compensatory neurohormonal activation. Several neurohormonal activations are present in HF supporting hemodynamics, but they appear to be deleterious in the long term on the myocardium, increasing progression of the HF and mortality. Blocking the renin–angiotensin–aldosterone system and the sympathetic system are now the mainstay of medical therapy in HF related to systolic dysfunction as they decrease mortality, hospitalisation rate and improve quality of life. Hence, the approach to patient with chronic heart failure should differ from that of patient with acute heart failure.     

Insuffisance rénale aiguë et infarctus cérébral au décours d’un traitement par immunoglobulines intraveineuses à fortes doses

Introduction. — Side-effects of immunoglobulins administered via the intravenous route are usually minor. However, acute renal failure and more rarely thrombotic events, including ischemic stroke, have been reported in association with immunoglobulin infusion. To our knowledge, no case of both acute renal failure and stroke following immunoglobulin has been described until now.Exegesis. — Two days after immunoglobulin infusion (2 g/kg), a patient who presented with autoimmune thrombocytopenia suffered severe acute renal failure associated with an ischemic stroke in the right anterior choroid artery territory. Moreover, the stroke worsened immediately following a second infusion (1 g/kg). Clinical and neuroradiological examinations were conducted.Conclusion. — Results indicate the need for both close monitoring of serum creatinine and diuresis before starting immunoglobulin therapy, and limiting the total dose to prevent thrombotic events such as stroke.